PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
12.50%
Gross profit growth 50-75% of AXSM's 18.30%. Martin Whitman would scrutinize competitive position.
No Data
No Data available this quarter, please select a different quarter.
37.48%
Similar R&D growth to AXSM's 36.26%. Walter Schloss would investigate industry innovation requirements.
21.30%
G&A growth while AXSM reduces overhead. John Neff would investigate operational differences.
100.00%
Marketing expense growth above 1.5x AXSM's 26.25%. Michael Burry would check for spending discipline.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth above 1.5x AXSM's 15.93%. Michael Burry would check for inefficiency.
29.39%
Total costs growth above 1.5x AXSM's 14.98%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
D&A reduction while AXSM shows 8.85% growth. Joel Greenblatt would examine efficiency.
-30.36%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.58%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
7.95%
Share count reduction below 50% of AXSM's 0.38%. Michael Burry would check for concerns.
7.95%
Diluted share reduction below 50% of AXSM's 0.38%. Michael Burry would check for concerns.